IRIS UniCatt

Ciccullo, Arturo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.521
AS - Asia 1.030
EU - Europa 799
SA - Sud America 216
Continente sconosciuto - Info sul continente non disponibili 71
AF - Africa 36
OC - Oceania 4
Totale 3.677
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.458
SG - Singapore 472
CN - Cina 227
SE - Svezia 212
BR - Brasile 184
IT - Italia 155
FR - Francia 116
DE - Germania 110
VN - Vietnam 78
IN - India 72
IE - Irlanda 44
BD - Bangladesh 37
CA - Canada 33
GB - Regno Unito 33
ID - Indonesia 33
FI - Finlandia 27
JP - Giappone 21
RU - Federazione Russa 19
MX - Messico 18
PL - Polonia 17
AR - Argentina 15
TR - Turchia 14
ES - Italia 13
IQ - Iraq 12
BE - Belgio 10
HK - Hong Kong 10
ZA - Sudafrica 10
KR - Corea 9
NL - Olanda 9
UA - Ucraina 9
CH - Svizzera 6
EC - Ecuador 5
KE - Kenya 5
LT - Lituania 5
MA - Marocco 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
JM - Giamaica 4
SA - Arabia Saudita 4
TN - Tunisia 4
AT - Austria 3
IR - Iran 3
JO - Giordania 3
MY - Malesia 3
PS - Palestinian Territory 3
TW - Taiwan 3
AU - Australia 2
CI - Costa d'Avorio 2
CO - Colombia 2
DZ - Algeria 2
EG - Egitto 2
EU - Europa 2
KW - Kuwait 2
NZ - Nuova Zelanda 2
PE - Perù 2
PT - Portogallo 2
TT - Trinidad e Tobago 2
TZ - Tanzania 2
UZ - Uzbekistan 2
YE - Yemen 2
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CM - Camerun 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PR - Porto Rico 1
PY - Paraguay 1
QA - Qatar 1
RO - Romania 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TG - Togo 1
UY - Uruguay 1
VE - Venezuela 1
VI - Stati Uniti Isole Vergini 1
ZM - Zambia 1
ZW - Zimbabwe 1
Totale 3.608
Salva come PNG Salva come JPEG
Città #
Chandler 314
Singapore 253
Ashburn 151
San Jose 118
New York 90
Beijing 70
Dublin 44
Rome 42
San Mateo 36
Boston 30
Jakarta 29
Princeton 28
Ho Chi Minh City 27
Los Angeles 27
The Dalles 27
Wilmington 27
Lauterbourg 24
Munich 21
Nanjing 21
Chicago 20
Frankfurt am Main 20
São Paulo 20
Tokyo 20
Dearborn 18
Marseille 18
Milan 18
Santa Clara 17
Helsinki 16
Redwood City 16
Cattolica 14
Hanoi 14
Dallas 12
Montreal 11
Paris 11
Brooklyn 10
Brussels 10
Hefei 10
London 10
Moscow 10
Orem 10
Toronto 10
Warsaw 10
Atlanta 9
Buffalo 9
Fairfield 9
Turku 9
Hong Kong 8
Jacksonville 8
Mexico City 8
Pune 8
Stockholm 8
Changsha 7
Guangzhou 7
Nuremberg 7
Da Nang 6
Hangzhou 6
Johannesburg 6
Philadelphia 6
Seattle 6
Shenyang 6
Belo Horizonte 5
Campinas 5
Council Bluffs 5
Dhaka 5
Houston 5
Jinan 5
Nanchang 5
Querétaro 5
San Francisco 5
Zurich 5
Ankara 4
Bexley 4
Busto Arsizio 4
Denver 4
Falkenstein 4
Jiaxing 4
Las Vegas 4
Miami 4
Mumbai 4
Ottawa 4
Seoul 4
Tianjin 4
Alcalá de Henares 3
Amman 3
Ann Arbor 3
Augusta 3
Baghdad 3
Belford Roxo 3
Chennai 3
Cleveland 3
Elk Grove Village 3
Haiphong 3
Hyderabad 3
Kingston 3
Kunming 3
Leawood 3
Manchester 3
Memphis 3
Nairobi 3
Naples 3
Totale 1.989
Salva come PNG Salva come JPEG
Nome #
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 196
Shall we dance? Extending tango's results to clinical practice 170
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 168
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients 160
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report 156
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 151
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 143
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 143
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 139
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 138
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 137
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice 133
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 131
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 130
Dolutegravir plus lamivudine for the treatment of HIV-1 infection 122
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 121
'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice 120
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 119
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 117
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study 108
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 107
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 105
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 104
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 104
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients 102
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 99
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study 93
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice 82
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 79
Totale 3.677
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.444
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.444
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022253 0 2 7 46 9 5 5 42 6 22 37 72
2022/2023684 102 96 63 106 39 71 33 57 78 2 25 12
2023/2024308 14 78 6 35 6 93 15 1 4 11 17 28
2024/2025526 13 11 41 30 71 24 25 26 63 39 93 90
2025/20261.379 187 26 70 198 299 45 243 63 91 97 24 36
2026/2027100 67 33 0 0 0 0 0 0 0 0 0 0
Totale 3.677